Article citationsMore>>

Heymach, J.V., Johnson, D.H., Khuri, F.R., Safran, H., Schlabach, L.L., Yunus, F., DeVore III, R.F., De Porre, P.M., Richards, H.M., Jia, X., Zhang, S. and Johnson, B.E. (2004) Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients with Sensitive Relapse Small-Cell Lung Cancer. Annals of Oncology, 15, 1187-1193. http://dx.doi.org/10.1093/annonc/mdh315

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.